1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Sanofi Acquires Dynavax

M&A Deal Summary

Sanofi Acquires Dynavax

On December 24, 2025, Sanofi acquired life science company Dynavax for 2.2B USD

Acquisition Highlights
  • This is Sanofi’s 23rd transaction in the Life Science sector.
  • This is Sanofi’s 7th largest (disclosed) transaction.
  • This is Sanofi’s 20th transaction in the United States.
  • This is Sanofi’s 6th transaction in California.

M&A Deal Summary
Date 2025-12-24
Target Dynavax
Sector Life Science
Buyer(s) Sanofi
Deal Type Add-on Acquisition
Deal Value 2.2B USD

Target

Dynavax

EmeryVille, California, United States
Dynavax is a bio-pharmaceutical company that develops products to treat allergy, inflammation-mediated diseases, infectious diseases and cancer. Dynavax's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax was founded in 1996 and is based in Emeryville, California.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Sanofi

Paris, France
Category Company
Founded 1994
Sector Life Science
Employees82,878
Revenue 44.3B EUR (2024)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company. Sanofi was founded in 1994 and is based in Paris, France.

DEAL STATS #
Overall 32 of 32
Sector: Life Science M&A 23 of 23
Type: Add-on Acquisition M&A Deals 25 of 25
State: California M&A 6 of 6
Country: United States M&A 20 of 20
Year: 2025 M&A 5 of 5
Size (of disclosed) 7 of 16
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-12-10 InduPro

Seattle, Washington, United States

InduPro is a biotechnology company defining and harnessing inherent and induced proximity biology to unlock next-generation therapeutics in cancer and autoimmune diseases. The Company develops therapeutics against novel, tumor-selective targets and co-target pairs using bispecific antibodies including antibody drug conjugates (ADCs) and T cell engagers (TCEs), fueling a robust pipeline of first- and best-in-class programs. InduPro is based in Seattle, Washington.

Buy -
Mergr

Solution for

Product

Company

Legal